Do analysts prefer SCNX or ZYBT?

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, equities analysts plainly believe Scienture is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SCNX or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Scienture. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scienture $430K 37.70 -$41.51M -$2.51 N/A Zhengye Biotechnology $116.36M 0.77 -$9.98M N/A N/A

Is SCNX or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -56.28% -44.76% Zhengye Biotechnology N/A N/A N/A

Is DWTX or SCNX more profitable?

Scienture's return on equity of -56.28% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Scienture N/A -56.28% -44.76%

Do analysts prefer RYM or SCNX?

Scienture has a consensus price target of $1.50, suggesting a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, RYM or SCNX?

RYTHM has higher revenue and earnings than Scienture. RYTHM is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 2.83 -$33.26M -$10.53 N/A Scienture $430K 37.70 -$41.51M -$2.51 N/A

Is RYM or SCNX more profitable?

Scienture has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Scienture N/A -56.28% -44.76%

Do analysts recommend SCNX or SCLX?

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SCNX or SCLX?

Scienture has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scienture $430K 37.70 -$41.51M -$2.51 N/A Scilex $33.86M 1.71 -$358.73M -$40.47 N/A

Is SCNX or SCLX more profitable?

Scienture has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -56.28% -44.76% Scilex -1,110.17% N/A -143.55%

Which has higher earnings & valuation, SCYX or SCNX?

SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SCYNEXIS $20.34M 2.51 -$8.61M -$3.84 N/A Scienture $430K 37.70 -$41.51M -$2.51 N/A

Is SCYX or SCNX more profitable?

Scienture has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Scienture's return on equity of -56.28% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -57.16% -39.48% Scienture N/A -56.28% -44.76%

Scienture (SCNX) Competitors

$0.40 +0.02 (+4.97%)

As of 02:37 PM Eastern

Compare

SCNX vs. ZYBT, DWTX, RYM, SCLX, and SCYX

Should you buy Scienture stock or one of its competitors? MarketBeat compares Scienture with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scienture include Zhengye Biotechnology (ZYBT), Dogwood Therapeutics (DWTX), RYTHM (RYM), Scilex (SCLX), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceuticals" industry.

How does Scienture compare to Zhengye Biotechnology?

Scienture (NASDAQ:SCNX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

5.7% of Scienture shares are owned by institutional investors. 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-56.28%	-44.76%
Zhengye Biotechnology	N/A	N/A	N/A

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, equities analysts plainly believe Scienture is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scienture has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.72, suggesting that its share price is 372% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Scienture.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	37.70	-$41.51M	-$2.51	N/A
Zhengye Biotechnology	$116.36M	0.77	-$9.98M	N/A	N/A

In the previous week, Zhengye Biotechnology had 5 more articles in the media than Scienture. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 0 mentions for Scienture. Zhengye Biotechnology's average media sentiment score of 0.29 beat Scienture's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Scienture	Neutral
Zhengye Biotechnology	Neutral

Summary

Scienture beats Zhengye Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Scienture compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 564.82%. Scienture has a consensus price target of $1.50, suggesting a potential upside of 275.94%. Given Dogwood Therapeutics' higher possible upside, equities research analysts plainly believe Dogwood Therapeutics is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scienture's return on equity of -56.28% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Scienture	N/A	-56.28%	-44.76%

Dogwood Therapeutics has higher earnings, but lower revenue than Scienture. Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Scienture	$430K	37.70	-$41.51M	-$2.51	N/A

Dogwood Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Scienture has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market.

In the previous week, Dogwood Therapeutics had 3 more articles in the media than Scienture. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 0 mentions for Scienture. Dogwood Therapeutics' average media sentiment score of 0.37 beat Scienture's score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Scienture	Neutral

Summary

Dogwood Therapeutics and Scienture tied by winning 6 of the 12 factors compared between the two stocks.

How does Scienture compare to RYTHM?

RYTHM (NASDAQ:RYM) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

RYTHM has a beta of 9.47, meaning that its stock price is 847% more volatile than the broader market. Comparatively, Scienture has a beta of 3.26, meaning that its stock price is 226% more volatile than the broader market.

RYTHM has higher revenue and earnings than Scienture. RYTHM is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.83	-$33.26M	-$10.53	N/A
Scienture	$430K	37.70	-$41.51M	-$2.51	N/A

6.0% of RYTHM shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 21.4% of Scienture shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Scienture has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Scienture	N/A	-56.28%	-44.76%

In the previous week, RYTHM had 4 more articles in the media than Scienture. MarketBeat recorded 4 mentions for RYTHM and 0 mentions for Scienture. RYTHM's average media sentiment score of 0.75 beat Scienture's score of 0.00 indicating that RYTHM is being referred to more favorably in the media.

Company	Overall Sentiment
RYTHM	Positive
Scienture	Neutral

Scienture has a consensus price target of $1.50, suggesting a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

RYTHM and Scienture tied by winning 8 of the 16 factors compared between the two stocks.

How does Scienture compare to Scilex?

Scienture (NASDAQ:SCNX) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Scienture has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market. Comparatively, Scilex has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

In the previous week, Scienture's average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score.

Company	Overall Sentiment
Scienture	Neutral
Scilex	Neutral

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 275.94%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scienture has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-56.28%	-44.76%
Scilex	-1,110.17%	N/A	-143.55%

Scienture has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	37.70	-$41.51M	-$2.51	N/A
Scilex	$33.86M	1.71	-$358.73M	-$40.47	N/A

5.7% of Scienture shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Scienture beats Scilex on 11 of the 14 factors compared between the two stocks.

How does Scienture compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, SCYNEXIS had 4 more articles in the media than Scienture. MarketBeat recorded 4 mentions for SCYNEXIS and 0 mentions for Scienture. SCYNEXIS's average media sentiment score of 0.72 beat Scienture's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Positive
Scienture	Neutral

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.34M	2.51	-$8.61M	-$3.84	N/A
Scienture	$430K	37.70	-$41.51M	-$2.51	N/A

SCYNEXIS has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Scienture has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market.

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 366.02%. Scienture has a consensus price target of $1.50, indicating a potential upside of 275.94%. Given SCYNEXIS's stronger consensus rating and higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scienture has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Scienture's return on equity of -56.28% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Scienture	N/A	-56.28%	-44.76%

Summary

SCYNEXIS beats Scienture on 9 of the 16 factors compared between the two stocks.

Get Scienture News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNX vs. The Competition

Export

Metric	Scienture	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.21M	$11.91B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.16	788.55	269.95	24.78
Price / Sales	37.70	968.18	650.49	107.95
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.23	10.32	11.25	6.43
Net Income	-$41.51M	$2.77B	$3.45B	$347.27M
7 Day Performance	3.10%	1.96%	3.49%	2.53%
1 Month Performance	7.81%	-1.59%	-0.66%	-1.03%
1 Year Performance	-81.00%	191.11%	77.20%	23.28%

Scienture Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNX Scienture	1.7327 of 5 stars	$0.40 +5.0%	$1.50 +275.9%	-81.9%	$16.21M	$430K	N/A	N/A	Upcoming Earnings
ZYBT Zhengye Biotechnology	0.5948 of 5 stars	$2.36 +84.4%	N/A	-63.7%	$60.66M	$16.64M	N/A	278	Gap Down High Trading Volume
DWTX Dogwood Therapeutics	2.983 of 5 stars	$1.83 +2.2%	$12.00 +555.7%	-62.6%	$60.20M	N/A	N/A	5	Upcoming Earnings
RYM RYTHM	1.1106 of 5 stars	$24.99 -1.8%	N/A	N/A	$55.44M	$17.28M	N/A	140	Earnings Report Gap Up
SCLX Scilex	0.2636 of 5 stars	$6.52 +0.8%	N/A	-55.8%	$54.94M	$30.25M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scienture (SCNX) Competitors

SCNX vs. ZYBT, DWTX, RYM, SCLX, and SCYX

How does Scienture compare to Zhengye Biotechnology?

Summary

How does Scienture compare to Dogwood Therapeutics?

Summary

How does Scienture compare to RYTHM?

Summary

How does Scienture compare to Scilex?

Summary

How does Scienture compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX vs. The Competition

Scienture Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scienture (SCNX) Competitors

SCNX vs. ZYBT, DWTX, RYM, SCLX, and SCYX

How does Scienture compare to Zhengye Biotechnology?

Do institutionals and insiders have more ownership in SCNX or ZYBT?

Is SCNX or ZYBT more profitable?

Do analysts prefer SCNX or ZYBT?

Which has more risk & volatility, SCNX or ZYBT?

Which has better earnings & valuation, SCNX or ZYBT?

Does the media refer more to SCNX or ZYBT?

Summary

How does Scienture compare to Dogwood Therapeutics?

Do insiders & institutionals hold more shares of DWTX or SCNX?

Do analysts rate DWTX or SCNX?

Is DWTX or SCNX more profitable?

Which has higher valuation and earnings, DWTX or SCNX?

Which has more volatility and risk, DWTX or SCNX?

Does the media refer more to DWTX or SCNX?

Summary

How does Scienture compare to RYTHM?

Which has more volatility & risk, RYM or SCNX?

Which has better earnings & valuation, RYM or SCNX?

Do institutionals and insiders hold more shares of RYM or SCNX?

Is RYM or SCNX more profitable?

Does the media prefer RYM or SCNX?

Do analysts prefer RYM or SCNX?

Summary

How does Scienture compare to Scilex?

Which has more risk and volatility, SCNX or SCLX?

Does the media favor SCNX or SCLX?

Do analysts recommend SCNX or SCLX?

Is SCNX or SCLX more profitable?

Which has stronger valuation and earnings, SCNX or SCLX?

Do institutionals & insiders have more ownership in SCNX or SCLX?

Summary

How does Scienture compare to SCYNEXIS?

Does the media prefer SCYX or SCNX?

Do institutionals & insiders have more ownership in SCYX or SCNX?

Which has higher earnings & valuation, SCYX or SCNX?

Which has more volatility & risk, SCYX or SCNX?

Do analysts recommend SCYX or SCNX?

Is SCYX or SCNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX vs. The Competition

Scienture Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools